Five-year bond attracts strong investor response as indigenous pharmaceutical firm targets greater local production
Nigeria's pharmaceutical manufacturing sector is set for a fresh boost after Emzor Pharma Funding SPV Plc raised N26.70bn through a five-year fixed-rate bond to finance the expansion of Emzor Pharmaceutical Industries Limited's manufacturing operations.
The Series 1 bond, which carries an interest rate of 19 per cent, was issued under the company's N40bn Bond Issuance Programme and subsequently listed on the FMDQ Exchange following approval by the Board Listings and Markets Committee of FMDQ Exchange.
The funds will be deployed primarily towards working capital requirements and the expansion of Emzor's manufacturing capacity, with a substantial portion earmarked for the completion of what the company described as Africa's first full-scale antimalarial Active Pharmaceutical Ingredient (API) manufacturing plant.
The development is expected to strengthen Nigeria's capacity to produce critical pharmaceutical inputs locally and reduce the country's dependence on imported APIs, which are essential components in the production of medicines.
Focus on local pharmaceutical production
The bond financing represents another major step in Emzor's efforts to deepen pharmaceutical manufacturing in Nigeria.
Emzor Pharma Funding SPV Plc was established specifically to raise capital for its sponsor, Emzor Pharmaceutical Industries Limited, a wholly indigenous Nigerian pharmaceutical company with operations across the domestic and regional markets.
The company's investment in an API manufacturing facility comes at a time when Nigeria continues to grapple with significant dependence on imported pharmaceutical ingredients and finished medicines.
By increasing domestic API production, the project is expected to strengthen the local pharmaceutical value chain, improve supply resilience and support the country's broader drive towards greater self-sufficiency in healthcare manufacturing.
‘An important step’
Chairman of Emzor, Emeka Okoli, described the N26.70bn bond issuance as a significant milestone in the company's expansion strategy.
According to him, the latest transaction is Emzor's second domestic bond and the strong response from investors, including the oversubscription of the offer, reflects confidence in the company's financial position and long-term growth prospects.
Okoli said the completion of the antimalarial API facility would represent a major development for Nigeria's pharmaceutical industry.
He noted that the project would strengthen domestic manufacturing capacity while helping to reduce the country's dependence on imported pharmaceutical ingredients.
The chairman's comments underscore the strategic importance of the facility beyond Emzor's own business expansion, particularly as Nigeria seeks to build a more resilient healthcare system capable of producing essential pharmaceutical inputs locally.
Investment in health security
The transaction was led by Renaissance Securities (Nigeria) Limited as lead sponsor, while FirstCap Limited and UCML Capital Limited acted as co-sponsors.
Chief Executive Officer of Renaissance Capital Africa, Samuel Sule, said the firm was pleased to lead the transaction, describing the bond as an important financing initiative for Nigeria's pharmaceutical manufacturing sector.
Sule said the funds would support the development of the API facility and contribute to national health security by expanding the country's domestic capacity to manufacture critical pharmaceutical inputs.
The investment, he added, could help address some of the structural challenges associated with dependence on imported pharmaceutical materials while strengthening the broader healthcare supply chain.
Capital market backs indigenous industry
The successful listing also highlights the growing role of Nigeria's debt capital market in providing long-term financing for indigenous businesses.
Group Chief Operating Officer of FMDQ Group Plc, Tumi Sekoni, said the transaction demonstrated the capacity of the Nigerian debt capital market to connect local businesses with the funding required to pursue large-scale expansion projects.
According to Sekoni, directing capital towards domestic pharmaceutical manufacturing could strengthen the healthcare value chain while contributing to the development of a deeper and more resilient financial market.
The Emzor transaction therefore represents more than a corporate fundraising exercise. It also illustrates how Nigeria's capital market can support investments in sectors considered critical to national development.
With the N26.70bn raised, Emzor now has additional funding to advance its manufacturing expansion and complete the antimalarial API project.
If successfully completed, the facility could mark an important milestone in Nigeria's efforts to produce more pharmaceutical inputs locally, reduce exposure to international supply disruptions and build greater resilience into the country's healthcare manufacturing ecosystem.